News about Clinical Trials

XORTX Unveils New Research on Genome-Wide Pathways in Gout

XORTX Therapeutics highlighted findings from recent independent, peer-reviewed research showing that multiple genetic factors are linked to over-expression of Xanthine Oxidase (XO), chronically elevated blood uric acid levels, and gout—further reinforcing the company’s strategy of targeting XO to treat gout, kidney, and related diseases.

Clinical Trials | 01/01/2026 | By News Bureau

Senhwa Expands Oncology Manufacturing Focus With CX-5461 - ADC Combination Trial

Senhwa Biosciences, Inc. has announced a significant clinical development milestone with its first-in-class investigational agent Pidnarulex (CX-5461) set to be evaluated in combination with the antibody–drug conjugate trastuzumab deruxtecan (Enhertu) in a phase 1b clinical trial.

Clinical Trials | 30/12/2025 | By Darshana

Diamyd Medical Advances Type I Diabetes Phase III Efficacy Readout by Nine Months

Diamyd Medical has aligned with the US FDA to accelerate the primary efficacy readout of its Phase 3 DIAGNODE-III trial in type 1 diabetes from 24 to 15 months, enabling results to be available nine months earlier than previously planned.

Clinical Trials | 30/12/2025 | By News Bureau

KEYTRUDA Plus Padcev Improves Survival Outcomes in MIBC

KEYTRUDA plus Padcev significantly improved survival and pathologic complete response rates in cisplatin-eligible patients with muscle-invasive bladder cancer when used before and after surgery.

Clinical Trials | 18/12/2025 | By News Bureau

US FDA Approves Phase III Trial of Cadonilimab Against Nivolumab in Gastric Cancer

The FDA’s clearance enables a global phase III study evaluating Cadonilimab, in combination with chemotherapy, as a first-line option for HER2-negative, unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma, directly comparing its efficacy to standard chemotherapy with or without Nivolumab.

Clinical Trials | 12/12/2025 | By Akanki |  126

J&J Reports 74% One-Year Disease-Free Survival with INLEXZO in High-Risk NMIBC

Johnson & Johnson reported strong new data from Cohort 4 of the SunRISe-1 study, showing that INLEXZO (gemcitabine intravesical system) achieved a 74 percent one-year disease-free survival rate in patients with BCG-unresponsive, high-risk papillary-only NMIBC, with over 95 percent progression-free and more than 92 percent avoiding bladder removal.

Clinical Trials | 06/12/2025 | By Dineshwori

ALS Association Announces USD 2M Support for Emerging ALS Treatments

The ALS Association has awarded $2 million through its Hoffman ALS Clinical Trial Awards Program to advance two early-stage therapeutic candidates, supporting efforts to accelerate the development of new treatments for the disease.

Clinical Trials | 06/12/2025 | By Dineshwori |  103

Immorta Bio Reports Tumour Reduction Across Multiple Cancer Models with SenoVax

Immorta Bio has reported promising pre-clinical results showing that its anti-aging vaccine, SenoVax, reduced tumours across multiple validated cancer models. Developed in collaboration with academic institutions, the platform aims to dismantle tumour defense mechanisms and offer a non-toxic, longevity-driven approach to cancer treatment.

Clinical Trials | 05/12/2025 | By Dineshwori |  247

Ascletis Advances First Oral Triple Agonist ASC37 to Clinical Development

Ascletis has selected ASC37—its first oral GLP-1R/GIPR/GCGR triple peptide agonist—for clinical development. Using the company’s POTENT technology, ASC37 showed markedly higher oral bioavailability and drug exposure than leading agents in non-human primate studies.

Clinical Trials | 01/12/2025 | By Dineshwori

New Innovation Hub to Make Maharashtra a Global Pharma & Biotech Hub

The government of Maharashtra plans to establish a state-of-the-art Life Sciences Innovation and Incubation Centre aimed at boosting research and development in pharmaceuticals, biotechnology, medical devices, diagnostics and digital health.

Clinical Trials | 29/11/2025 | By Darshana |  119